Strategic development projects
IN IMMUNOLOGY
• Ongoing project to apply for marketing authorisation in the United States of America.
• Development of a new route of administration.
IN HAEMOSTASIS
Recombinant activated factor VII for certain forms of haemophilia:
• Ongoing clinical development to extend indications in the United States of America.
• Marketing authorisation requests planned in Colombia and Algeria.
IN INTENSIVE CARE:
Fibrinogen:
• Ongoing clinical development to extend indications in Europe.
• Ongoing project to apply for marketing authorisation in the United States of America.
• Development of a new dosage strength.